I am very confident in the Xtoll product. And let's not forget there are a lot of other auto-immune disorders where it may be of use.
But I am also increasingly concerned that, if the directors have no qualms about lining their own pockets via bogus 'performance rights', perhaps they will also have no problem selling out cheaply if the deal looks after their own personal interests.